Radical cystectomy as standard treatment of muscle-invasive urothelial carcinoma of the urinary bladder cures less than 50% of patients with locally advanced bladder cancer. We compared two adjuvant combination chemotherapies in patients with stage pT3a-4a and/or pathologic node-positive transitional-cell carcinoma of the bladder after radical cystectomy.
INTRODUCTION
Radical cystectomy is recommended as curative treatment for locally advanced bladder cancer including tumor stages pT3 and pT4a and/or involvement of regional lymph nodes. However, more than half of these patients experience relapse, with distant metastasis being the predominant form of disease recurrence. Therefore, combination chemotherapy has been investigated as neoadjuvant or adjuvant adjunctive treatment in numerous trials. A recent meta-analysis on neoadjuvant chemotherapy for invasive bladder cancer described a modest but clear improvement in survival, encouraging the use of platinum-based combination therapy. 1 For the adjuvant approach, three randomized trials have suggested a relapsefree survival improvement for patients receiving combination chemotherapy after radical cystectomy compared with patients undergoing surgery alone. [2] [3] [4] The combination regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC), which was first reported as a palliative approach for advanced metastatic urothelial carcinoma in 1985, 5 has succeeded as a gold standard treatment in randomized trials. 6, 7 The first randomized trial comparing adjuvant M-VAC or methotrexate, vinblastine, epirubicin, and cisplatin (M-VEC) to radical cystectomy alone found a significant progressionfree survival improvement of 50% for the adjuvant group 40 months after surgery. 3 Despite the efficacy of M-VAC or M-VEC combination therapy, severe hematologic and nonhematologic toxicity and a treatment-related mortality rate of up to 4% have caused concern.
The present study was initiated in 1994 as a noninferiority trial of a reduced chemotherapy regimen consisting of cisplatin plus methotrexate (CM) compared with conventional M-VEC, with the intention of finding a less toxic but effective regimen for the adjuvant treatment of patients with resected locally advanced bladder cancer with no substantial loss of efficacy.
PATIENTS AND METHODS
The study protocol was reviewed and approved by the committee of the "Arbeitsgemeinschaft Urologische Onkologie" of the German Cancer Society as well as local ethics committees of participating centers.
Eligibility
Patients eligible for the randomization process had to meet the following inclusion criteria. Disease status after radical cystectomy must be histologically confirmed stage pT3a-4a and/or pathologic node-positive transitional-cell carcinoma of the bladder (1997 TNM classification 8 ). Squamous cell carcinoma and/or adenocarcinoma components were allowed if transitional-cell carcinoma was present. Radical cystectomy denoted the removal of the entire bladder, prostate, and seminal vesicles in men and removal of anterior pelvic organs in the female, including, if indicated, a portion of the anterior vagina. The method of urinary diversion was left to the discretion of the investigator. Bilateral pelvic lymph node dissection was a prerequisite for correct staging and included a full dissection of the lymph nodes bordered by the internal iliac arteries, external iliac arteries, and the pelvic floor bilaterally including obturator nodes. Any evidence of macroscopic or microscopic incomplete resection (tumor-positive margin of the specimen or grossly enlarged unresected lymph nodes) was considered an exclusion criterion. Distant metastasis was excluded by preoperative staging, including at least chest x-ray and abdominal ultrasound. Furthermore, patients between 18 and 70 years old were included if they had a Karnofsky performance score of at least 80 with adequate renal and liver function as well as bone marrow reserve (measured creatinine clearance Ն 70 mL/min, serum creatinine Յ 1.3 mg/dL, bilirubin Ͻ 1.5 mg/dL, ALT or AST Ͻ 60 U/L, WBC count Ն 3.0 ϫ 10 9 /L, platelets Ն 150 ϫ 10 9 /L, and hemoglobin Ն 10 g/dL). Local intravesical adjuvant chemotherapy or immunotherapy before radical cystectomy was allowed. Furthermore, a written informed consent according to institutional and federal guidelines had to be signed by the patient. Patients were ineligible if the time interval between radical cystectomy and the first day of chemotherapy exceeded 4 months and if they had used any investigational agent in the months before enrollment onto the study.
Treatment Plan
The on day 2, and cisplatin 70 mg/qm 2 on day 2) was administered every 28 days for a maximum of three cycles.
The following dose adjustments were planned. Methotrexate was omitted if the leukocyte count was less than 2.5 ϫ 10 9 /L or the thrombocyte count was less than 100 ϫ 10 9 /L. The beginning of a new cycle was delayed until the leukocyte count was greater than 3.0 ϫ 10 9 /L and the thrombocyte count was greater than 100 ϫ 10 9 /L. Doses of cisplatin and methotrexate were reduced by 50% if measured creatinine clearance was 50 to 70 mL/min, or the drugs were omitted if the creatinine clearance was less than 50 mL/min. Patients were to receive full supportive care. Use of growth factors was recommended only in case of leukopenic fever, dose omissions for methotrexate and vinblastine as a result of leukopenia, or delay of a consecutive cycle as a result of leukopenia. Hematologic and nonhematologic toxicity was graded according to the WHO grading system. Study drug therapy was discontinued if there was evidence of progressive disease under therapy, if the attending physician considered a change of therapy to be in the best interest of the patient, if the patient requested discontinuation, or if the drug exhibited unacceptable toxicity.
Follow-Up of Patients
Follow-up of both treatment groups occurred at 3-month intervals for 2 years, then at 6-month intervals for 3 years, and yearly thereafter. Follow-up consisted of physical examination, abdominal ultrasound and chest radiography, and computed tomography scanning or bone scanning as clinically indicated. The site and date of the first relapse, as well as the date and the reason in case of death, were recorded. Relapse was defined as the detection of at least one suspicious lesion that could not be identified by histologic, clinical, or laboratory criteria as an independent secondary malignancy. In case of relapse, it was left to the discretion of the patient and the attending physician whether further therapy, such as second-line chemotherapy, radiation, or surgical treatment, was initiated.
Statistical Methods
The primary basis for the statistical planning and analysis of the trial was the noninferiority version of the log-rank test for equivalence of two survivor functions 9 satisfying an ordinary proportional hazards model in the sense of Cox. 10 The test was applied with an equivalence margin of ␦ ϭ .15, which gives the maximum tolerable difference of progression-free survival probabilities to be expected under both treatments for the same time since cystectomy. Practical implementation of the procedure was performed by estimating the regression coefficient ␤ of a proportional hazards model, with the indicator of treatment group CM as the only covariate, and comparing the right-hand limit of a 90% CI for the hazard ratio (HR) ϭ e ␤ to 1.5077 as a critical upper bound. For the purpose of checking the adequacy of the proportional hazards assumption, the procedure implemented by the S-plus (Statistical Sciences, Seattle, WA) function cox.zph was used (for a detailed description of the statistical rationale behind it, see Therneau and Grambsch 11 ) . Because the P value obtained from this test turned out to be as large as .45, there was no reason to question the appropriateness of the model.
However, estimation of median progression-free survival time was based on a fully parametric model because both observed survivor functions dropped below 50% so late that the number of patients still at risk was too small for providing a sufficiently accurate estimate of the conditional probability of surviving the interval containing the observed median. Of the standard parametric models, the log-normal was the model that showed the best fit to the data. Accordingly, confidence limits for the median progression-free survival time were computed by transforming those for the expected value of the distribution of log T.
In addition to progression-free survival time, which had been chosen as the primary end point for the confirmatory analysis of this trial, the same techniques were also applied to the data obtained for the length of survival and time until death from the specific tumor. All eligible patients who received any adjuvant treatment were included in the analysis of possible toxic effects. The incidences of WHO grade 3 and 4 toxicities were compared using Fisher's exact test for homogeneity of two binomial distributions.
RESULTS
Between January 1, 1994, and September 30, 2000, 335 patients were registered onto the trial (Fig 1) . Eight patients (2.4%) were deemed ineligible because inclusion criteria were not met (age, renal function, metastatic disease at time of radical cystectomy, secondary malignancy, and withdrawal of consent). The remaining 327 patients were equally assigned to adjuvant systemic chemotherapy with CM or M-VEC by randomization after having signed informed consent.
Demographic factors were similar between the two groups ( Table 1) . Median age was 60.5 years, and the ratio of males to females was almost 4:1. More than half of the patient group (56.6%) had tumor-positive regional lymph nodes. The median follow-up time for patients living free of relapse at the time of analysis was 42 months.
Treatment
The median time from surgery to chemotherapy was 56 days in both arms. Of the 163 patients assigned to receive adjuvant CM, 123 (75.5%) completed three cycles as planned (Table 2 ); 12.9% (21 of 163 patients) discontinued treatment early because of toxic effects or for other reasons.
Nineteen patients (11.7%) declined treatment, and four patients (2.5%) died during the course of treatment. One patient died of cardiac failure (day 18 of a third cycle), two patients experienced severe bone marrow toxicity after two cycles, and one patient developed lethal pneumonia after one cycle.
Of the 164 patients assigned to the M-VEC arm, 113 (68.9%) completed three cycles; 21.4% (35 of 164 patients) stopped treatment early. Sixteen patients (9.8%) declined treatment, and one patient (0.6%) died during treatment with M-VEC as a result of cardiac dysfunction. All patients were analyzed as belonging to the treatment arm assigned by randomization, adopting the intent-to-treat principle.
Surgical Procedures
The only surgery-related requirements for eligibility were radical cystectomy with curative intent and en bloc resection of the tumor with negative margins, as well as absence of metastatic or unresected transitional-cell carcinoma. However, because patients were usually identified postoperatively, specific surgical and histopathologic procedures could not be required.
Toxicity
Hematologic toxic effects predominated. The most common hematologic toxic effect was leukopenia, with a significantly higher rate in patients treated with M-VEC compared with CM (22.2% v 7.0%, respectively). Except for a significant difference in grade 3 alopecia in favor of CM (1.9% in CM v 24.7% in M-VEC), no difference was observed for other hematologic or nonhematologic factors. Four patients (2.5%) died as a result of a toxic effect attributed to CM chemotherapy, and one patient (0.6%) died as a result of therapy in the M-VEC arm. This difference of therapy-related mortality was not statistically significant (Fisher's exact test, P ϭ .371). The toxic effects classified as WHO grade 3 or higher that occurred among treated patients are listed in Table 3 .
Progression-Free Survival
The median follow-up period for patients living free of progression was greater than 3 years. Tumor relapse was reported in 46.0% of the patients (75 of 163 patients) in the CM group and 44.5% of patients (73 of 164 patients) in the M-VEC group. The median duration of progression-free survival was 43.4 months in the CM arm and 49.7 months in the M-VEC arm by intent-to-treat analysis ( Table 4 ). The 5-year progression-free survival rates were 46.3% in the CM treatment group and 48.8% in the M-VEC group (Fig 2) . The HR for disease progression in the CM group, as compared with the M-VEC group, was 1.13 (90% CI, 0.86 to 1.48; P ϭ .0403).
In the subgroup analyses of patients with lymph nodepositive disease, the median progression-free survival was 36.2 months (90% CI, 27.5 to 47.7 months) in the CM group and 32.4 months (90% CI, 24.8 to 42.3 months) in the M-VEC group. The 5-year progression-free survival rates of patients with lymph node-positive disease were 41.9% in the CM group and 40.1% in the M-VEC group (Fig 3) . The HR for disease progression in the CM group, as compared with the M-VEC group, was 0.95 (90% CI, 0.67 to 1.33; P ϭ .0126).
In the analyses of patients with tumor extension beyond the bladder wall but without lymph node involvement, the median progression-free survival was 52.0 months (90% CI, 36.5 to 74.2 months) in the CM arm and 87.7 months (90% CI, 59.8 to 128.6 months) in the M-VEC arm. The 5-year progression-free survival rates were 51.5% in the CM group and 60.8% in the M-VEC group (Fig 4) . The HR for disease progression in the CM group, as compared with the M-VEC group, was 1.46 (90% CI, 0.94 to 2.29; P ϭ .4571).
Tumor-Specific and Overall Survival
Sixty-five patients in the CM treatment group (39.9%) and 62 patients in the M-VEC treatment group (37.8%) died of tumor disease during the follow-up period. The median duration of tumor-specific survival was 57.3 months in the CM group and 63.3 months in the M-VEC group (Fig 5) . The HR for tumor-related death in the CM group, as compared with the M-VEC group, was 1.13 (90% CI, 0.84 to 1.51; P ϭ .0528).
The 5-year rates of tumor-specific survival were 52.0% in the CM group and 52.3% in the M-VEC group (Table 4 , Fig 5) . In the CM and M-VEC arms, 14 patients (8.6%) and 15 patients (9.1%) died as a result of causes not related to tumor, respectively. The median duration of overall survival was 47.1 months in the CM group and 51.8 months in the M-VEC group (Table 4 , Fig 6) . The HR for death irrespective of cause in the CM group, as compared with the M-VEC group, was 1.10 (90% CI, 0.88 to 1.44; P ϭ .0255).
The 5-year rates of overall survival were 46.1% in the CM group and 45.1% in the M-VEC group.
Site of Tumor Relapse
Classification of first relapses with regard to site resulted as follows (Table 5) . Local recurrence only occurred in 12 patients in the CM group (7.3%) and seven patients in the M-VEC group (4.3%). Lymphatic relapse only, which was typically encountered as retroperitoneal lymph node disease, was reported in 4.3% of CM patients (seven of 163 patients) and 6.1% of M-VEC patients (10 of 164 patients). Visceral metastases (without bone metastases) were found in 20.2% of patients in the CM group (33 of 163 patients) and 15.9% of patients in the M-VEC group (26 of 164 patients); at least 12.3% of CM patients (20 of 163 patients) and 15.2% of M-VEC patients (25 of 164 patients) developed bone metastases.
DISCUSSION
The frequent occurrence of tumor relapses after radical cystectomy for locally advanced bladder cancer, the favorable results of three former adjuvant trials, [2] [3] [4] and the limited tolerability of adjuvant M-VEC or M-VAC combination chemotherapy provided the rationale for the present study. After introducing effective M-VAC combination chemotherapy in urothelial cancer in 1985, 5 two successive, randomized, phase III trials demonstrated the superiority of the M-VAC regimen in advanced urothelial cancer compared with single-agent cisplatin 7, 12 or with cisplatin, cyclophosphamide, and doxorubicin combination therapy. 6 Because of the pronounced hematologic and nonhematologic toxicity with M-VAC or M-VEC combination therapy, other potentially less toxic combination therapies, such as CM, have been investigated in advanced urothelial cancer. 13, 14 Neoadjuvant administration of chemotherapy has been exceedingly investigated compared with the adjuvant approach for patients with a high risk of relapse undergoing definite treatment by surgery or radiation. Although the majority of individual neoadjuvant studies was not able to demonstrate a significant survival advantage for preemptive chemotherapy compared with definitive treatment alone, a recent meta-analysis based on individual patient data from 10 randomized neoadjuvant trials was able to demonstrate a significant 13% reduction in the risk of death (HR ϭ 0.87; 95% CI, 0.78 to 0.98; P ϭ .016), which was equivalent to a 5% absolute overall survival benefit at 5 years from 45% to 50%.
1 This meta-analysis also stated that a significant advantage exists using platinum-based combination chemotherapy compared with single-agent platinum. The most recent neoadjuvant study, which was not included in the former meta-analysis, achieved a survival advantage with borderline significance for 154 patients assigned to three cycles of neoadjuvant M-VAC combination therapy versus 153 patients randomly assigned to surgery alone (median survival, 77 months in the neoadjuvant arm v 46 months in the surgery-only arm; P ϭ .06).
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Whether neoadjuvant or adjuvant application of systemic chemotherapy for locally advanced bladder cancer is the preferable treatment modality remains a matter of debate. To date, only one study has investigated the neoadjuvant and adjuvant treatment strategy directly. 16 Similar to our experience, 40% of patients in this trial with histologically proven regional lymph node metastasis experienced long-term progression-free survival in both treatment arms.
In contrast to neoadjuvant administration of chemotherapy, proponents of adjuvant chemotherapy for locally advanced bladder cancer emphasize optimal patient selection based on exact assessment of histopathologic tumor stage. This allows the selection of patients with the highest risk for relapse, and only minimal occult tumor burden after radical cystectomy needs to be treated. Subsequently, improvement of recurrence-free survival by adjuvant combination chemotherapy was corroborated by three individual randomized controlled studies from Germany and the United States for the adjuvant administration of combination chemotherapy after radical cystectomy. [2] [3] [4] Skinner et al 2 randomly assigned 91 locally advanced bladder cancer patients to radical cystectomy plus four cycles of adjuvant chemotherapy (predominantly cisplatin, cyclophosphamide, and doxorubicin combination therapy) versus surgery alone. The trial was stopped because of an interim analysis that demonstrated a significant disease-free survival advantage for the adjuvant treatment arm 5 years after cystectomy (51% for adjuvant chemotherapy v 34% for surgery alone, P Ͻ .011). Stöckle et al 3 terminated their study after an interim analysis of 49 patients demonstrated a significant disease-free survival difference of 50% at 3.5 years in favor of 26 patients receiving adjuvant treatment with M-VAC or M-VEC compared with the control group (63% for adjuvant chemotherapy v 13% for cystectomy alone; P ϭ .0005).
A third randomized trial with a favorable result for adjuvant combination chemotherapy performed at Stanford University compared adjuvant cisplatin, methotrexate, and vinblastine combination chemotherapy to cystectomy alone. 4 In contrast to the former two studies, deferred chemotherapy on progression was suggested by the protocol for patients assigned to the nonadjuvant arm. This study was also closed before accrual of the preplanned number of patients because of a significant difference in progressionfree survival in favor of patients receiving adjuvant chemotherapy. Median time to progression for the 25 patients assigned to the adjuvant treatment arm was 37 months versus 12 months in the cystectomy-alone group (P Ͻ .01), whereas overall survival was not significantly different. Criticisms of all three former trials have been summarized by Sylvester and Sternberg 17 and address small sample size, early stopping of patient entry and premature closure, statistical analyses, reporting of results, and drawing conclusions.
Adjuvant chemotherapy trials for invasive bladder cancer that did not find a significant difference for patients receiving adjuvant chemotherapy compared with a surgeryonly group have been reported from Switzerland, 18 Italy, 19 and Germany. 20 This may be attributed to the exclusion of lymph node-positive patients 19 and to the administering of only single-agent cisplatin as adjuvant treatment to a predominantly pT2pN0 population. 18 Only limited information on the degree of toxicity has been revealed from any of these adjuvant trials. Reports on palliative M-VAC or M-VEC combination chemotherapy causing grade 3 to 4 myelosuppression in more than half of the patients, a 25% incidence of nadir sepsis, and drugrelated deaths in at least 3% of patients 21 prompted investigators to search for more tolerable but still active regimens. Efficacy of CM combination therapy as implemented for the current trial had been reported previously for 53 patients with advanced urothelial cancer.
13 Although the majority of patients had dose omissions or delays, an overall response rate of 46% was noted. The standard M-VEC treatment arm of the current trial incorporated epirubicin instead of doxorubicin, as in the original M-VAC schema, because cardiotoxicity was of concern at the time of drafting the protocol.
Because of the nature of the current trial testing for noninferior efficacy of the reduced combination (CM) compared with the full combination (M-VEC), the results may only lend support to but not prove the superiority of adjuvant combination chemotherapy compared with surgery alone. Remarkably, the 5-year progression-free survival rate of greater than 40% for lymph node-positive disease after radical cystectomy plus adjuvant combination chemotherapy (CM or M-VEC) represents an average standard of care of 40 uro-oncologic centers in Germany. Retrospective studies of patients with lymph node-positive bladder cancer receiving adjuvant chemotherapy after radical cystectomy versus surgery alone reported significant 5-year overall survival advantages of 43% v 17% (P ϭ .03) 22 and 45% v 21% (P ϭ .031) 23 for the adjuvant group, respectively. A similar survival comparison from the Mayo Clinic demonstrated a 5-year tumor-specific survival advantage of 55% v 32% (P ϭ .005) in favor of the adjuvant chemotherapy group compared with surgery alone, respectively, 24 notwithstanding the limitation that any retrospective result may be biased by patient selection. Finally, the recurrence-free survival rate of 41% at 5 years for all lymph node-positive patients (n ϭ 185) in our trial is slightly higher than 39% rate that was recently reported from another North American center of excellence administering adjuvant chemotherapy to 139 patients with lymph node-positive disease.
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When assessing the possible effects of baseline factors (eg, age, sex, tumor stage, blood cell counts, renal and liver function, and size of recruiting center) on the risk of progression using multivariate Cox regression analysis, the only significant predictor was the number of tumorpositive lymph nodes (data not shown). The current trial did not control for either the number of lymph nodes Abbreviations: CM, cisplatin plus methotrexate; M-VEC, methotrexate, vinblastine, epirubicin, and cisplatin.
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www.jco.org removed during radical cystectomy or the extent of pelvic lymphadenectomy because patients were usually identified postoperatively to be eligible for this trial. Therefore, a specific surgical and histopathologic protocol could not be required. Some authors have suggested a survival improvement for patients undergoing extensive lymphadenectomy with cystectomy in a retrospective survey, 25-27 whereas others have seen a significant survival advantage with extensive lymphadenectomy only in patients with organ confined (Յ pT2) bladder cancer. 28 Future trials on adjuvant chemotherapy for locally advanced bladder cancer may focus on this issue with more precision. As previously reported for the palliative indication of combination chemotherapy in unresectable advanced urothelial cancer, the gold standard status of M-VAC therapy has declined. 29 Results of a large, multinational, phase III trial comparing M-VAC with gemcitabine plus cisplatin combination therapy showed similar response rates and comparable overall survival in 405 patients. Although patient numbers and study design of this trial did not allow for the testing of significant noninferiority, gemcitabine plus cisplatin has become a well-established Abbreviations: CM, cisplatin plus methotrexate; M-VEC, methotrexate, vinblastine epirubicin, and cisplatin; PFS, progression-free survival; TSS, tumor-specific survival.
‫ء‬
Parametric estimates based on an accelerated failure-time model with log-normal survival distribution.
†Log-rank test for one-sided equivalence (noninferiority).
Fig 2.
Progression-free survival among all eligible patients, according to treatment group assignments. HR, hazard ratio; CM, cisplatin and methotrexate; M-VEC, methotrexate, vinblastine, epirubicin, and cisplatin. Progression-free survival among all eligible patients with lymph node-negative disease, according to treatment group assignments. HR, hazard ratio; CM, cisplatin and methotrexate; M-VEC, methotrexate, vinblastine, epirubicin, and cisplatin.
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www.jco.orgregimen for the treatment of advanced bladder cancer because of significantly less clinically relevant toxicity and better cost effectiveness.
The implications of our results must be assessed with a view to the equivalence margin of 0.15, which had been specified in the protocol for the difference between the respective survivor functions at any point of time. Thus, the major statistical hypothesis that could be established by means of our data does not rule out the possibility that the full combination therapy comprising all four drugs is more efficient than the reduced chemotherapy regimen. But we can be certain that this advantage, which is supported by the positive signs of the point estimates obtained from the total samples, fails to be of significant clinical relevance. For the adjuvant indication of combination chemotherapy with curative intent in resected locally advanced bladder cancer, the current report provides evidence that the efficacy of the less toxic regimen CM cannot be considered substantially inferior to the efficacy of M-VEC.
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Fig 6.
Overall survival among all eligible patients, according to treatment group assignments. HR, hazard ratio; CM, cisplatin and methotrexate; M-VEC, methotrexate, vinblastine, epirubicin, and cisplatin. Abbreviations: CM, cisplatin plus methotrexate; M-VEC, methotrexate, vinblastine, epirubicin, and cisplatin.
‫ء‬
Because patients could have relapses at multiple sites, the total number of relapses is greater than the number of patients in each group who experienced relapses.
†Sites of relapse were classified as local if tumor was detected in the region of the excised bladder, as nodal if tumor was detected in regional or distant lymph nodes, as osseous if metastasis was present in bone, and as visceral if metastasis was present in other organs. 27. Herr HW: Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 61: [105] [106] [107] [108] 2003 28. Poulsen AL, Horn T, Steven K: Radical cystectomy: Extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 160: [2015] [2016] [2017] [2018] [2019] 1998 29. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000 Bladder Cancer "Adjuvant-Lite": Tastes Great (works as well) and Less Filling (less toxic)? In this issue, Lehmann et al 1 report that cisplatin plus methotrexate (CM) is not inferior to methotrexate, vinblastine, epirubicin, and cisplatin (M-VEC) in the adjuvant treatment of patients with locally advanced bladder cancer after surgery. The report suggests a possible new standard of care. Do the data support this conclusion? To answer that question, a short review of pre-existing data and statistics is needed.
One prerequisite for evaluating treatments in the perioperative setting is the demonstration of efficacy in advanced disease. The rationale has been that regimens meeting such a milestone may be incrementally more effective when the tumor is microscopic, exploiting the enhanced sensitivity of rapidly proliferating cells. This has been the evolution of treatment for transitional-cell carcinoma (TCC) of the bladder. In advanced disease, carefully conducted phase II studies showed transient partial responses with single agents in the 1970s; durable complete remissions were demonstrated when effective agents were combined in three-and four-drug combinations in the 1980s; and prospective randomized comparisons of these combinations provided evidence for survival benefits in the 1990s. In individual trials, methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) conferred a survival benefit compared with single-agent cisplatin and cisplatin, doxorubicin, and cyclophosphamide 2, 3 ; and cisplatin, methotrexate, and vinblastine (CMV) demonstrated a survival benefit compared with methotrexate and vinblastine. 4 These results established M-VAC and CMV as treatment standards for patients with metastatic disease.
In the new millennium, adequately powered prospective randomized trials with sufficient follow-up of M-VAC and CMV as neoadjuvant therapy were reported, demonstrating survival benefits compared with no chemotherapy and establishing neoadjuvant chemotherapy as the standard management for patients with muscle-invasive disease. In the largest trial of neoadjuvant chemotherapy in TCC, 976 patients with clinical T2-4a disease were randomly assigned to neoadjuvant CMV versus no chemotherapy, combined with cystectomy, radiation therapy, or both as management of the primary tumor. The trial, which was powered to detect an absolute improvement in survival of 10% (from 50% to 60%), was initially reported as negative. 5 However, with 7 years of follow-up, a significant reduction in the hazard ratio for death was observed for the chemotherapy-treated patients (hazard ratio ϭ 0.85; 95% CI, 0.72 to 1.0; P ϭ .048). 6 In the second trial, INT 0080, 317 patients with clinical stage T2-4a TCC were randomly assigned to receive three cycles of neoadjuvant M-VAC followed by radical cystectomy or radical cystectomy alone. 7 This trial was powered to detect a Ն 50% improvement in median survival with the combined approach. With a median follow-up of almost 9 years, a 21-month difference was observed for chemotherapy-treated patients versus patients who did not receive chemotherapy (77 v 46 months, respectively; P ϭ .06). The absolute survival benefit at 5 years was 14%, and the hazard ratio for survival was 0.75 (95% CI, 0.57 to 1.0), favoring the neoadjuvant arm.
Given these results, why isn't the neoadjuvant approach practiced more widely? There are several reasons. First, the inaccuracies of clinical staging make the assessment of which patients are destined to metastasize and who, thus, need systemic therapy to achieve cure less precise. Second, the delay in definitive therapy in patients who do not respond to treatment raises concerns regarding compromise of curability. Third, the development of internal urinary reservoirs makes the objective of bladder preservation less tenable for the majority of patients. These factors have led many urologists and urologic oncologists to adopt a treatment policy in which the recommendation for
chemotherapy is considered in the postoperative adjuvant setting, as opposed to the neoadjuvant setting.
Unfortunately, the available data supporting an adjuvant approach are less compelling because, in large part, of deficiencies in trial design. At least five randomized trials have evaluated the role of postoperative chemotherapy in bladder cancer, [8] [9] [10] [11] [12] of which the largest trial accrued 91 patients. The results suggested survival benefits in two trials, with no difference in the other three trials. Of those trials deemed to be positive, patients with pT3b-T4a and/or node-positive disease were randomly assigned to three cycles of M-VAC or M-VEC or no further treatment after cystectomy. 9 Although 100 patients were required to detect a 35% improvement in disease-free survival, the trial was terminated after 49 patients were enrolled when an interim analysis showed a significant improvement in 3-year disease-free survival for the chemotherapy arm versus the no chemotherapy arm (63% v 13%, respectively; P ϭ .0015). A follow-up report indicated an improvement in overall survival as well. This trial has been criticized because the results were not analyzed on an intent-to-treat basis; patients who were assigned to chemotherapy but did not receive treatment were included as controls, and treated patients included patients who were treated during the same interval but who did not undergo random assignment. In the second trial, patients with pT3-4 and/or nodepositive TCC were randomly assigned to receive four cycles of cisplatin, doxorubicin, and cyclophosphamide or no further treatment after cystectomy. 10 Although a significant difference in median survival was observed favoring chemotherapy compared with no chemotherapy (4.3 v 2.4 years, respectively), the curves crossed at the 48% level, the ultimate accrual of 91 patients fell far short of the originally planned accrual goal, and the Wilcoxon analysis used favored early, rather than late, events.
Is it reasonable to extrapolate the results from the neoadjuvant studies to the adjuvant setting? Many oncologists feel that it is, citing large trials in other malignancies that suggest no difference between these two approaches.
13 Although no large trials have directly compared neoadjuvant and adjuvant therapy in bladder cancer, a trial reported by Millikan et al 14 randomly assigned 140 patients to receive either two courses of neoadjuvant M-VAC followed by cystectomy plus three additional cycles of chemotherapy or initial cystectomy followed by five cycles of adjuvant chemotherapy. This small randomized trial suggested no difference in outcomes based on the sequence of administration of therapy.
Another barrier to the widespread adoption of perioperative chemotherapy in bladder cancer has been concern regarding the toxicity associated with multiagent cisplatinbased regimens. The toxicities of M-VAC in advanced disease include febrile neutropenia, mucositis, hearing loss, renal impairment, and peripheral neuropathy; treatmentrelated deaths occur in 2% to 4% of patients. Over the last decade, several groups have designed studies in patients with metastatic disease to address whether the same anticancer effects can be achieved with fewer side effects. One study showed similar response rates, response durations, and survival with reduced toxicity for gemcitabine plus cisplatin compared with M-VAC. 15 As a result, gemcitabine plus cisplatin has become a favored regimen in patients with advanced TCC.
The trial reported by Lehmann et al 1 in this issue extends this concept of similar efficacy with improved tolerability to the adjuvant setting. In this trial, M-VEC (M-VAC with epirubicin substituted for doxorubicin to minimize cardiotoxicity) was compared with CM as adjuvant therapy in patients with pT3a-4a and/or node-positive TCC of the bladder. A noninferiority design was chosen to establish CM as a less toxic regimen with comparable efficacy. The primary end point was progression-free survival, with the equivalence margin set at 0.15, and the upper bound of the hazard ratio was 1.5. The treatment arms were balanced with regard to baseline demographics and pathologic stage, and the number of patients completing all three cycles of chemotherapy was similar. The results showed a median time to progression of 49.7 months for patients treated with M-VEC compared with 43.4 months for CM-treated patients. The hazard ratio for recurrence of 1.131 (90% CI, 0.863 to 1.482) favored M-VEC, and the authors concluded that, "For the adjuvant indication of combination chemotherapy with curative intent in resected locally advanced bladder cancer, the current report provides evidence that the efficacy of the less toxic regimen of CM cannot be considered substantially inferior to the efficacy of M-VEC."
Less filling and tastes great? Is less toxic really as effective? Have we established a new standard? Several questions remain. First, is the control regimen, adjuvant M-VEC, a standard of care? Second, what is known about CM, the experimental regimen, in advanced disease? Third, what is the basis for the statistical design and sample size to prove CM is not inferior? And finally, is CM less toxic than M-VEC?
Even if we accept that adjuvant M-VAC/M-VEC is a standard of care, data to support CM as the experimental arm are limited. Unlike M-VAC and CMV, CM has not been shown to confer a survival benefit in patients with metastatic TCC. In a randomized trial of 108 patients comparing CM with single-agent cisplatin, CM was not superior to cisplatin alone. 16 Because CM has not been shown to be superior to single-agent cisplatin and single-agent cisplatin is ineffective in the perioperative setting, 17 the use of CM as the experimental arm is a leap of faith.
Does the trial really show noninferiority? Before addressing this question, we must consider the question of superiority. To show an absolute difference in survival of 10% between the two groups would require the random assignment of approximately 1,000 patients. 18 How can it be concluded that CM was noninferior when only 327 patients were accrued? Central to the noninferiority trial design is the equivalence margin, which is the degree of efficacy that the investigators are willing to give up for some decrement in toxicity. In this trial, an equivalence margin of 0.15 was chosen, with an upper bound of the hazard ratio at 1.5. In other words, the authors were willing to accept up to a 50% increase in the hazard of disease progression for a less toxic regimen. This seems excessive when the treatment objective is to prolong life and may exceed the benefit of even the most effective chemotherapy. On the basis of the actual accrual, the study met their primary end point, with an upper bound of the hazard ratio of 1.48; or, stated differently, the hazard of disease progression with CM could have been increased by up to 48% compared with M-VEC. Therefore, noninferiority is established only if the treating clinician is prepared to accept and offer to his or her patients a regimen (CM) that could have up to a 48% likelihood of being inferior to the alternative (M-VEC). To us, this risk seems too great, and a new standard of care is not established.
Finally, was CM really less toxic than M-VEC? Here, as well, the data are not convincing. Although the frequency of grade 3 neutropenia and alopecia was higher on the M-VEC arm, the rates of grade 4 neutropenia, febrile neutropenia, infection, and treatment-related deaths were similar. Information regarding other toxicities was not provided, and quality-of-life end points were not addressed prospectively in the study design. Notably, the toxicity observed with M-VAC/M-VEC in patients with metastatic disease has not been encountered to the same degree in the perioperative setting, and those toxicities that are encountered can be reduced substantially with hematopoietic growth factors and antiemetics, which were supportive measures that were not available when M-VAC was originally designed.
The investigators set out with the noble goal of defining a less toxic alternative adjuvant regimen for locally advanced TCC of the bladder. Unfortunately, the question of whether CM is equivalent to the three-and four-drug regimens of CMV and M-VEC (M-VAC) with respect to survival remains open. At present, on the basis of a survival benefit demonstrated in randomized comparative trials, neoadjuvant cisplatin-based combination chemotherapy followed by definitive treatment of the primary tumor is the current standard of care for patients with muscle-invasive bladder cancer. Patients who do not receive neoadjuvant therapy should be considered for enrollment onto clinical trials. The utility of adjuvant chemotherapy in bladder cancer remains controversial. To address this issue, the European Organization for Research and Treatment of Cancer is randomly assigning 1,344 patients with pT3-4 and/or node-positive disease to postoperative cisplatinbased chemotherapy or a similar regimen at the time of relapse. Convinced of the benefit of adjuvant chemotherapy, the Cancer and Leukemia Group B (CALGB)/Clinical Trial Support Unit is seeking to define an optimal treatment by randomly assigning 800 patients to either gemcitabine plus cisplatin or doxorubicin plus gemcitabine followed by paclitaxel plus cisplatin (CALGB 90104) More answers will only become available if we support these efforts.
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